Cargando…

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Airaksinen, A, Benesova, M, de France, G, Frånberg, H, Ghezzi, C, Gracheva, N, Haddad, F, Helariutta, K, Jakobsson, U, Jensen, M, Kesenheimer, Ch, Köster, U, Montavon, G, Müller, C, Pichler, B, Pouget, JP, Rolle, A-M, Schibli, R, Severin, G, Türler, A, Umbricht, Ch, Wiehr, S, van der Meulen, N, Vermeulen, E
Publicado:	2016
Materias:	Detectors and Experimental Techniques
Acceso en línea:	http://cds.cern.ch/record/2120135

Ejemplares similares

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Domnanich, Katharina, et al.
Publicado: (2014)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Dorrer, H, et al.
Publicado: (2011)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Production and separation of (43)Sc for radiopharmaceutical purposes
por: Domnanich, Katharina A., et al.
Publicado: (2017)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Koester, Ulli, et al.
Publicado: (2018)

Radiopharmaceuticals and other compounds labelled with short-lived radionuclides
por: Welch, Michael J
Publicado: (2013)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

(188)Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy
por: Boschi, Alessandra, et al.
Publicado: (2017)

Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy
por: Gracheva, Nadezda, et al.
Publicado: (2019)

Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application
por: Müller, Cristina, et al.
Publicado: (2018)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Köster, Ulli
Publicado: (2017)

Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges
por: Salih, Suliman, et al.
Publicado: (2022)

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

Alpha-PET for Prostate Cancer: Preclinical investigation using (149)Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute
por: Müller, Cristina, et al.
Publicado: (2019)

Development and optimization of targeted radionuclide tumor therapy using folate based radiopharmaceuticals
por: Reber, Josefine Astrid
Publicado: (2015)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
por: Guzik, Patrycja, et al.
Publicado: (2020)

(47)Sc as useful β(–)-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes
por: Domnanich, Katharina A., et al.
Publicado: (2017)

Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides
por: Li, Wei Bo, et al.
Publicado: (2022)

Prospects in Folate Receptor-Targeted Radionuclide Therapy
por: Müller, Cristina, et al.
Publicado: (2013)

Palmitic Acid-Conjugated Radiopharmaceutical for Integrin α(v)β(3)-Targeted Radionuclide Therapy
por: Yang, Guangjie, et al.
Publicado: (2022)

Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
por: Deberle, Luisa M., et al.
Publicado: (2020)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Evaluation of Acridine Orange Derivatives as DNA-Targeted Radiopharmaceuticals for Auger Therapy: Influence of the Radionuclide and Distance to DNA
por: Pereira, Edgar, et al.
Publicado: (2017)

[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
por: Chan, Chung Ying, et al.
Publicado: (2023)

Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide
por: Idrissou, Malick Bio, et al.
Publicado: (2021)

Introduction to Radiobiology of Targeted Radionuclide Therapy
por: Pouget, Jean-Pierre, et al.
Publicado: (2015)

Preclinical investigations and first-in-human application of $^{152}$Tb-PSMA-617 for PET/CT imaging of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Preclinical investigations and first-in-human application of (152)Tb-PSMA-617 for PET/CT imaging of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

An innovative gamma-ray spectrometry system using a compact and portable CZT detector for radionuclidic purity tests of PET radiopharmaceuticals
por: Vichi, Sara, et al.
Publicado: (2016)

Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates
por: Teze, David, et al.
Publicado: (2017)

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
por: Haller, Stephanie, et al.
Publicado: (2016)

Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics
por: Müller, Cristina, et al.
Publicado: (2016)

Radiopharmaceuticals for therapy
por: Knapp, F F (Russ), et al.
Publicado: (2016)

PET Radiopharmaceuticals
por: Shahhosseini, Soraya
Publicado: (2011)

Pharmacovigilance in radiopharmaceuticals
por: Kumar, Rishi, et al.
Publicado: (2016)

International Committee for Radionuclide Metrology Symposium on Radionuclide Metrology and its Applications
por: Bortel, G, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_r9kn19fpdl49ov9gu9b95ouc0a